Dosing Information for Retatrutide Vials
A 12 mg vial of retatrutide provides exactly one subcutaneous injection, as the medication is administered as a single weekly dose.
Standard Dosing Protocol
The dosing regimen for retatrutide follows a structured escalation schedule 1, 2:
- Starting dose: 2 mg subcutaneously once weekly
- Maintenance doses: 4 mg, 8 mg, or 12 mg subcutaneously once weekly
- Dose escalation: Gradual titration from 2 mg starting dose to higher maintenance doses (4 mg, 8 mg, or 12 mg) based on tolerability and clinical response 1, 2
Vial-to-Injection Conversion
Each dose represents one complete injection 1, 2:
- A 12 mg vial = 1 injection (12 mg dose)
- A 8 mg vial = 1 injection (8 mg dose)
- A 4 mg vial = 1 injection (4 mg dose)
- A 2 mg vial = 1 injection (2 mg dose)
Therefore, your 12 mg vial provides exactly 1 subcutaneous injection at the 12 mg maintenance dose.
Clinical Context
The 12 mg dose demonstrated the most robust efficacy in clinical trials 1, 2:
- Type 2 diabetes: HbA1c reduction of -2.02% at 24 weeks 1
- Obesity: Mean weight reduction of -24.2% at 48 weeks 2
- Liver fat reduction: -82.4% reduction in hepatic fat content at 24 weeks 3
Administration Considerations
Retatrutide is administered via subcutaneous injection once weekly 1, 2. The medication follows similar administration principles to other GLP-1 receptor agonists, where each vial or pen contains a single predetermined dose 4. Starting with a lower dose (2 mg) and gradually escalating helps mitigate gastrointestinal side effects, which are dose-dependent 1, 2.